Genome-wide association study on coronary artery disease in type 1 diabetes suggests beta-defensin 127 as a risk locus
Anni A. Antikainen(University of Helsinki), Per‐Henrik Groop(University of Helsinki), Romain Charmet(Inserm), Erkka Valo(University of Helsinki), Anna Syreeni(Helsinki University Hospital), Samy Hadjadj(Université de Poitiers), Daniel Gordin(Helsinki University Hospital), Niina Sandholm(University of Helsinki), Valma Harjutsalo(Research Council of Finland), Amy Jayne McKnight(Queen's University Belfast), David‐Alexandre Trégouët(Université de Bordeaux), Peter Rossing(Steno Diabetes Centers), Tarunveer S. Ahluwalia(Steno Diabetes Centers), Alexander P. Maxwell, Carol Forsblom(University of Helsinki)
Cited by 28
Related Papers
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
|New England Journal of Medicine|2024|1.5k